So could that be the reason why they enthusiastically want to join the new IO study with durvalumab and bavituximab? chemo alone wasn't good but with bavituximab there is a progress and with PD-L1 .....well maybe that could be the right combotherapy they want for their patients.
Market Data 
Markets 
AI
